Capitalmind
Capitalmind
Actionable insights on equities, fixed-income, macros and personal finance Start 14-Days Free Trial
Actionable investing insights Get Free Trial

942 ArticlesPremium

1 / 95

Premium: Why the TCS Buyback Last Time Saw Full Acceptance

We spoke of the TCS Buyback in a recent post: Deep inside the TCS Buyback is a tax efficient dividend. There’s an experimental in progress where ...
Charts-Analysis.jpg

Varroc Engineering: Not Quite Rocking

The listing of Varroc Engineering managed to benefit only the Tata Group. The IPO investors have lost more than three-fifths of their investments. Even the ...
Varroc-scaled.jpg

A Special Situation Opportunity Only For Those That Don’t Pay Tax

In Capitalmind Premium, we run a bunch of "experimentals". These are ideas that may not apply to everyone equally, or may have a very short term focus, or have ...
Special-Situation-scaled.jpg

CM Multicap Portfolio: 12 out of 15 stocks deliver strong earnings growth in Q2 – The Report Card

A round up of Q2 Earnings reports of Capitalmind LongTerm Multicap Portfolio ...
Earnings-Report-1.jpg

The Pitfalls of Mid and Small Cap Investing

All investors want to own quality companies in their portfolios, these are all weather companies which if held over long periods of time give satisfactory ...
Group-3.jpg

How have Index Inclusions & Exclusions performed?

How does getting added to or getting removed from the NIFTY affect a stock's performance? Should you buy index inclusions for the passive inflows that will ...
Featured-Image-13.jpeg

Blockbuster Earnings backed by Strong Demand for Balkrishna Industries

Highlight of Balkrishna's 2nd quarter earnings Strong sales growth of 46% on the back of agricultural tyre ...
Earnings-Report-1.jpg

Gland Pharma IPO: Should you invest?

Hyderabad based Gland Pharma will be launching the biggest IPO in Indian Pharma sector on 9th November. It’s one of the fastest growing B2B player in the ...
Gland-pharma-Featured-image-2.jpg

Can you really beat the market? Introducing the Capitalmind Premium League

It's that time of the year. When the COVID-impacted 2020 version of the Dream11 Indian Premier League winds down, and financial media is rife with Diwali picks ...
Premium-League.jpg

A good quarter despite tepid sales growth for Dr Lal PathLabs

Dr Lal Pathlabs, a leading diagnostic company has come up with its Q2 Results. We look at the results and management commentary in this post. ...
Earnings-Report-1.jpg